Merck KGaA Moves 2d EGFR Agent Into Full Development; Erbitux On Track
Executive Summary
Merck KGaA is moving the fully humanized epidermal growth factor receptor blocking antibody EMD-72000 into Phase II studies this year
You may also be interested in...
Erbitux Oncologic Potential Endorsed By FDA, Bristol During House Hearing
ImClone's oncologic agent Erbitux is "an active anticancer agent," Bristol-Myers Squibb and FDA Oncologic Drug Products Division Director Richard Pazdur, MD, agreed during a June 13 Energy & Commerce/Oversight Subcommittee hearing
Merck KGaA Cetuximab European Filing To Include 330 Colorectal Patients
Merck KGaA's European licensing application for cetuximab (ImClone's Erbitux) will include 330 colorectal cancer patients
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011